Meeder Asset Management’s Cardlytics CDLX Stock Holding History

Meeder Asset Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-17	Closed	-$4K	–	2099
2020 Q1	$4K	Buy	+17	New	+$12K	﹤0.01%	1851

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Meeder Asset Management's CDLX Position: Q2 2020 in Review

Meeder Asset Management sold out of Cardlytics (CDLX) in Q2 2020, closing a stake of 17 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in CDLX in Q1 2020 and held it in 1 quarter. The position peaked at $4K in Q1 2020. 164 funds tracked by Wall St. Rank hold CDLX as of Q2 2020.

Meeder Asset Management reported no remaining Cardlytics position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 17 Cardlytics shares in Q2 2020, an estimated $4K.
Meeder Asset Management first reported a position in Cardlytics in Q1 2020 and held it in 1 quarter.
Meeder Asset Management's Cardlytics position peaked at $4K in Q1 2020.
164 funds tracked by Wall St. Rank held Cardlytics as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.